Treatment of coexistent psoriasis and lupus erythematosus - 13/01/15
Abstract |
Background |
The coexistence of psoriasis and lupus erythematosus (LE) is rare. Anecdotal evidence suggests that anti–tumor necrosis factor alfa (TNF-α) agents may be efficacious in LE, although their use is commonly avoided in this disease because of concern for lupus flare.
Objective |
We sought to describe the epidemiology, serologic findings, and therapeutic choices in patients with coexistent psoriasis/psoriatic arthritis and LE and to determine the risk of lupus flares with TNF-α inhibitors.
Methods |
We performed a retrospective multicenter study of patients given the diagnoses of psoriasis (or psoriatic arthritis) and lupus erythematosus (systemic LE or cutaneous LE, including either subacute cutaneous LE or discoid LE) at 2 academic tertiary-care centers.
Results |
A total of 96 patients with a mean age of 56 years was included. We report higher-than-expected rates of white race and psoriatic arthritis. One clinical lupus flare was observed in a patient receiving a TNF-α inhibitor, resulting in an incidence of 0.92% lupus flares per patient-year of TNF-α inhibitor use.
Limitations |
Retrospective chart review, small sample size, and limited documentation.
Conclusion |
Anti–TNF-α agents, ustekinumab, and abatacept may be valid treatment options for patients with concomitant LE and psoriasis. Clinical lupus flares in LE patients treated with TNF-α inhibitors were infrequent.
Le texte complet de cet article est disponible en PDF.Key words : psoriasis, lupus erythematosus, tumor necrosis factor alfa
Abbreviations used : ANA, dsDNA, DLE, LE, Ps, PsA, SCLE, SLE, TNF-α
Plan
Funding sources: None. |
|
Conflicts of interest: None declared. |
Vol 72 - N° 2
P. 253-260 - février 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?